Y.D. More Investments Ltd Raises Stock Holdings in Brainsway Ltd. Sponsored ADR $BWAY

Y.D. More Investments Ltd grew its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 559.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 114,962 shares of the company’s stock after buying an additional 97,537 shares during the period. Y.D. More Investments Ltd owned 0.59% of Brainsway worth $2,187,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BWAY. UBS Group AG grew its stake in shares of Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after buying an additional 60,877 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after acquiring an additional 20,706 shares in the last quarter. Millennium Management LLC boosted its holdings in Brainsway by 69.6% in the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after acquiring an additional 16,354 shares in the last quarter. Centiva Capital LP purchased a new stake in shares of Brainsway in the third quarter worth $181,000. Finally, Eagle Global Advisors LLC increased its holdings in shares of Brainsway by 19.3% during the third quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company’s stock valued at $1,120,000 after acquiring an additional 12,000 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

Brainsway Price Performance

Shares of BWAY opened at $13.57 on Monday. The business has a 50-day simple moving average of $12.73 and a two-hundred day simple moving average of $10.14. Brainsway Ltd. Sponsored ADR has a 52 week low of $3.92 and a 52 week high of $14.65. The stock has a market cap of $543.21 million, a price-to-earnings ratio of 54.28 and a beta of 1.10.

Brainsway (NASDAQ:BWAY) last announced its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $14.55 million for the quarter, compared to the consensus estimate of $14.02 million. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. On average, equities analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BWAY shares. Northland Securities set a $15.00 target price on shares of Brainsway in a report on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a report on Monday, December 29th. HC Wainwright reduced their price target on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, March 12th. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Finally, Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Brainsway currently has a consensus rating of “Buy” and a consensus price target of $15.00.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.